| Not Yet Recruiting | LIAISON NES Influenza (FLU) A/B, Respiratory Syncytial Virus (RSV), & Coronavirus Disease 2019 (COVID-19) in S NCT06392451 | DiaSorin Molecular LLC | N/A |
| Withdrawn | A Study to Look at the Health Outcomes of Patients With COVID-19 and Influenza. NCT06163677 | Pfizer | — |
| Completed | LIAISON NES Influenza (FLU) A/B & Coronavirus Disease 2019 (COVID-19) Clinical Agreement in Australia NCT05897515 | DiaSorin Molecular LLC | N/A |
| Completed | Evaluation of KGR Prescriptions in Suppressing COVID-19 Infection. NCT06291883 | Sheng-Teng Huang | Phase 1 |
| Withdrawn | Leidos-Enabled Adaptive Protocol for Clinical Trials (LEAP-CT) in Hospitalized Patients With COVID-19 (Addendu NCT05085574 | Leidos Life Sciences | Phase 2 |
| Completed | Chlorpheniramine Nasal Spray to Accelerate COVID-19 Clinical Recovery in an Outpatient Setting: ACCROS-III NCT05886829 | Dr. Ferrer BioPharma | Phase 2 / Phase 3 |
| Completed | SARS-CoV-2 Nucleic Acid Detection Kit Clinical Performance Study NCT05492227 | TransGen Biotech Co., LTD | — |
| Unknown | A Phase Ia Clinical Study to Evaluate the Safety, Tolerability, PK and Immunogenicity of YBSW015 in Healthy Su NCT05369754 | Yabao Pharmaceutical Group | EARLY_Phase 1 |
| Unknown | Comparison of General Characteristics of Patients Diagnosed COVID-19 (Coronavirus )Positive Followed In Servic NCT05092568 | Saglik Bilimleri Universitesi | — |
| Completed | Evaluation of the AudibleHealth Dx AI/ML-Based Dx SaMD Using FCV-SDS in the Diagnosis of COVID-19 Illness: Cli NCT05364268 | AudibleHealth AI, Inc. | — |
| Completed | Huashi Baidu Granule in the Treatment of Pediatric Patients With Mild Coronavirus Disease 2019 NCT05501288 | Shanghai Children's Medical Center | N/A |
| Unknown | SOLIDARITY Finland Plus Long-COVID NCT05220280 | Clinical Urology and Epidemiology Working Group | Phase 4 |
| Active Not Recruiting | A Study to Look at the Health Outcomes of Patients With COVID-19 and Influenza NCT05160636 | Pfizer | — |
| Terminated | Leidos-Enabled Adaptive Protocol (LEAP-CT) for Evaluation of Post-exposure Prophylaxis for Newly-infected COVI NCT05077969 | Leidos Life Sciences | Phase 2 |
| Completed | LEAP-CT for Treatment of COVID-19 Patients (Master Protocol) NCT05077332 | Leidos Life Sciences | Phase 2 |
| Unknown | Prone Positioning in COVID-19 Patients NCT05150847 | Tepecik Training and Research Hospital | N/A |
| Completed | Chlorpheniramine Nasal Spray to Accelerate COVID-19 Clinical Recovery in an Outpatient Setting: ACCROS-I NCT05449405 | Dr. Ferrer BioPharma | Phase 2 / Phase 3 |
| Unknown | Masitinib in Patients With Symptomatic Mild to Moderate COVID-19 NCT05047783 | AB Science | Phase 2 |
| Withdrawn | LB1148 for Pulmonary Dysfunction Associated With COVID-19 Pneumonia NCT04390217 | Leading BioSciences, Inc | Phase 2 |
| Unknown | Clinical Study on the Immune Program of Recombinant Novel Coronavirus（COVID-19) Vaccine (CHO Cell) NCT05128643 | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | Phase 3 |
| Completed | Inhaled Interferon α2b for the Treatment of Coronavirus Disease 19 (COVID-19) NCT04988217 | Pontificia Universidad Catolica de Chile | Phase 1 / Phase 2 |
| Unknown | Clinical Trials of the Consistency and Non-inferiority Bridging Between Batches of Recombinant New Coronavirus NCT05091411 | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | Phase 3 |
| Completed | Clinical Study of Recombinant Novel Coronavirus（COVID-19） Vaccine (CHO Cell) Combined With Influenza Vaccine NCT05107375 | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | Phase 3 |
| Completed | Immunogenicity and Safety Evaluation of Recombinant Novel Coronavirus Vaccine (CHO Cells) in Enhancing Immunit NCT05089045 | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | N/A |
| Unknown | Proof of Principle Study to Evaluate the Safety, PK, Viral Shedding and Efficacy of Pentarlandir™ UPPTA for Pa NCT04911777 | SyneuRx International (Taiwan) Corp | Phase 2 |
| Recruiting | Cardiac Magnetic Resonance Tissue Characterization in COVID-19 Survivors NCT05164744 | Weill Medical College of Cornell University | — |
| Terminated | Study of Varespladib in Patients Hospitalized With Severe COVID-19 NCT04969991 | Ophirex, Inc. | Phase 2 |
| Completed | Tele-Physiotherapy After COVID-19 Hospitalization NCT04895371 | Tehran University of Medical Sciences | N/A |
| Completed | Immunogenicity After COVID-19 Vaccines in Adapted Schedules NCT06189040 | Universiteit Antwerpen | Phase 4 |
| Unknown | Identify Coronavirus Disease by Chest X-ray NCT05216471 | Assiut University | — |
| Completed | Follow-up of Covid-19 Long Term Sequelae NCT05097677 | Azienda Ospedaliera Universitaria Integrata Verona | — |
| Terminated | Study to Evaluate Safety and Efficacy of Carrimycin for Treatment of Severe Coronavirus Disease 2019 (COVID-19 NCT04672564 | Shenyang Tonglian Group CO., Ltd | Phase 3 |
| Completed | Double Blind, Placebo Controlled Study of Safety and Efficacy of Leronlimab in Patients With "Long" COVID-19 NCT04678830 | CytoDyn, Inc. | Phase 2 |
| Completed | Awake Prone Positioning for Non-intubated COVID-19 Patients NCT04760561 | Damanhour University | N/A |
| Completed | Long-term COVID-19 Immune Response in a Vulnerable Neighbourhood in Argentina NCT04673279 | Hospital Italiano de Buenos Aires | — |
| Completed | Association of Androgenetic Alopecia and Severity of Coronavirus Disease 2019 (COVID-19). NCT04898166 | Syeda Mahanum Ali | — |
| Completed | A Placebo Controlled Trial of Bempegaldesleukin (BEMPEG; NKTR-214) With Standard of Care in Patients With Mild NCT04646044 | Nektar Therapeutics | Phase 1 |
| Completed | Fostamatinib for Hospitalized Adults With COVID-19 NCT04579393 | National Heart, Lung, and Blood Institute (NHLBI) | Phase 2 |
| Completed | Cutaneous Manifestations of Coronavirus Disease 2019(COVID-19). NCT05094687 | Jinnah Postgraduate Medical Centre | — |
| Completed | Study of M5049 in Participants With COVID-19 Pneumonia (ANEMONE) NCT04448756 | EMD Serono Research & Development Institute, Inc. | Phase 2 |
| Unknown | Olfactory and Neurosensory Rehabilitation in COVID-19-related Olfactory Dysfunction NCT04900415 | Ivan FN Hung MD | Phase 2 |
| Completed | Impact of Changes in the Use of Care and Reorganization of the Healthcare System Linked to the Covid-19 Outbre NCT04979208 | University Hospital, Bordeaux | — |
| Completed | Evolution of Coronavirus Disease 2019 (COVID-19) Patients in Extremadura NCT04724850 | Juan Fernando Masa Jiménez | — |
| Completed | Controlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY Disease NCT04394117 | The George Institute | Phase 4 |
| Unknown | Neurologic Manifestations of COVID-19 NCT04386083 | University of the Philippines | — |
| Unknown | Masitinib Combined With Isoquercetin and Best Supportive Care in Hospitalized Patients With Moderate and Sever NCT04622865 | AB Science | Phase 2 |
| Completed | Tigerase® Efficacy and Safety as Part of Complex Therapy in Patients With COVID-19 NCT04459325 | AO GENERIUM | Phase 3 |
| Completed | COVID-19 Associated Lymphopenia Pathogenesis Study in Blood NCT04401436 | National Institute of Allergy and Infectious Diseases (NIAID) | — |
| Unknown | Detection Rate of SARS-CoV-2 in Male Genitourinary System and Its Impact on Male Reproductive Health. NCT04388631 | Tongji Hospital | — |
| Unknown | 1,3,7-Trimethylxanthine as a Treatment of COVID-19: Results of a Controlled Study NCT04395742 | Poitiers University Hospital | — |
| Completed | Evaluate the Efficacy & Safety of Leronlimab in Patients With Severe or Critical COVID-19 NCT04347239 | CytoDyn, Inc. | Phase 2 |
| Unknown | Covid-19 Associated Coagulopathy Predicted by Thrombodynamic Markers (CoViTro-I) NCT05330832 | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | — |
| Completed | Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate COVID-19 NCT04343651 | CytoDyn, Inc. | Phase 2 |
| Completed | Autoimmunity Contributes to the Severe Progression of COVID-19 NCT04967781 | Zhongnan Hospital | — |
| Completed | Registry of COVID-19 Patients at AOUI Verona NCT04497194 | Azienda Ospedaliera Universitaria Integrata Verona | — |
| Withdrawn | The Effect of T89 on Improving Oxygen Saturation and Clinical Symptoms in Patients With COVID-19 NCT04285190 | Tasly Pharmaceuticals, Inc. | N/A |
| Withdrawn | Humanistic Care in Healthcare Workers in Coronavirus Disease 2019 NCT04283838 | Second Affiliated Hospital of Xi'an Jiaotong University | N/A |
| Withdrawn | Clinical Outcomes of Patients With COVID19 NCT04280913 | Guangzhou Institute of Respiratory Disease | — |
| Withdrawn | Humanistic Care in Patients With Coronavirus Disease 2019 NCT04283825 | Second Affiliated Hospital of Xi'an Jiaotong University | N/A |
| Unknown | Sequential Oxygen Therapy Strategy for Patients With COVID-19 NCT04312100 | Henan Provincial People's Hospital | — |
| Completed | The Clinical Difference Between the Nonfatal Patients and the Fatal Patients With Severe COVID-19 NCT04403009 | The First Affiliated Hospital of Guangzhou Medical University | — |
| No Longer Available | Expanded Access Remdesivir (RDV; GS-5734™) NCT04302766 | U.S. Army Medical Research and Development Command | — |